Global Peyronie’s Disease Treatment Market Insights Forecasts to 2033

• The Global Peyronie’s Disease Treatment Market Size was Valued at USD 1.25 Billion in 2023
• The Market Size is Growing at a CAGR of 7.93% from 2023 to 2033
• The Worldwide Peyronie’s Disease Treatment Market Size is Expected to Reach USD 2.68 Billion by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Peyronie’s Disease Treatment Market Size is Anticipated to Exceed USD 2.68 Billion by 2033, Growing at a CAGR of 7.93% from 2023 to 2033.

Market Overview

Peyronie's disease is a condition characterized by the formation of scar-like tissue in the penis, which can cause changes in the penis shape, such as curvature, indent, or shortening. These changes can make it difficult or impossible for men to have intercourse, and may also lead to erectile dysfunction. The disease typically occurs in two phases acute (active) and chronic (stable). Urologists often treat the condition without surgery during the active phase, while men with small plaques, no pain, and no sex issues may not require treatment. Pain from the plaque is typically treated with anti-inflammatories like NSAIDs. As per the data provided by the National Institute of Health, Peyronie's disease affects around 1 in 100 US men over 18 years old.

Report Coverage

This research report categorizes the market for the global Peyronie’s disease treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global Peyronie’s disease treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global Peyronie’s disease treatment market.

Driving Factors

The market for Peyronie's disease treatment is driven by increasing awareness and diagnosis, advancements in medical technology, and improved treatment outcomes. The aging population, particularly men over 40, is more susceptible to the condition. Rising healthcare expenditure, patient preference for minimally invasive treatments, and research into innovative therapies are also driving the market. The availability of better diagnostic tools and treatment options, along with an emphasis on improving patient quality of life, are key factors driving the market.

Restraining Factors

Peyronie's disease treatment faces challenges due to the high costs of advanced therapies, limited awareness and stigma, and reluctance to undergo invasive procedures. Patients may be hesitant due to potential complications or perceived risks. The lack of universally effective treatments and variability in individual responses complicates management.

Market Segmentation

The global Peyronie’s disease treatment market share is classified into route of administration, treatment, and end-user.

• The injectable segment is expected to hold the largest share of the global Peyronie’s disease treatment market during the forecast period.   

Based on the route of administration, the global Peyronie’s disease treatment market is divided into oral, topical, and injectable. Among these, the injectable segment is expected to hold the largest share of the global Peyronie’s disease treatment market during the forecast period. The injectable segment is expected to experience significant growth in Peyronie's disease treatment market due to the increasing use of collagenase injections like Xiaflex, which target fibrous plaque responsible for penile curvature. These non-surgical treatments offer a minimally invasive option, reducing recovery time and improving patient outcomes. The growing adoption of these therapies and advancements in injectable formulations make this segment poised for rapid expansion.

• The collagenase injections segment is expected to grow at the fastest CAGR of the global Peyronie’s disease treatment market during the forecast period.   

Based on the treatment, the global Peyronie’s disease treatment market is divided into collagenase injections, shockwave therapy, surgery, oral medications, and topical treatments. Among these, the collagenase injections segment is expected to grow at the fastest CAGR in the global Peyronie’s disease treatment market during the forecast period. This minimally invasive treatment targets plaque-causing penile curvature, improving symptoms without surgery. The growing preference for non-surgical treatments, patient awareness, and favorable clinical outcomes are driving demand for collagenase injections. As research continues to improve the efficacy and safety profile of this treatment, its adoption is expected to expand, fueling growth in this segment.

• The specialty clinics segment is expected to grow at the fastest CAGR in the global Peyronie’s disease treatment market during the forecast period.   

Based on the end-user, the global Peyronie’s disease treatment market is divided into hospitals, specialty clinics, and ambulatory surgical centers. Among these, the specialty clinics segment is expected to grow at the fastest CAGR in the global Peyronie’s disease treatment market during the forecast period. The Specialty Clinics segment is expected to experience significant growth in Peyronie's disease treatment market due to their specialized care, advanced treatments, and personalized care. As more patients seek expert care, demand for these services is rising. Specialty clinics offer personalized treatment approaches and shorter wait times compared to hospitals, making them attractive options.

Regional Segment Analysis of the Global Peyronie’s Disease Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global Peyronie’s disease treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the global Peyronie’s disease treatment market over the predicted timeframe. The region is dominating the global Peyronie's disease treatment market due to its high prevalence, established healthcare infrastructure, and advanced treatment options. The US leads the market with high diagnosis rates and access to innovative therapies. Strong healthcare expenditure, favorable reimbursement policies, and key pharmaceutical companies contribute to its dominance in the market.

Asia-Pacific is expected to grow at the fastest pace in the global Peyronie’s disease treatment market during the forecast period. The growth of the Peyronie's disease market in Asia-Pacific countries is fueled by increased awareness, improved healthcare infrastructure, and rising healthcare expenditures. The aging male population and increased availability of advanced medical treatments, along with a growing focus on sexual health and improved healthcare access, contribute to the market's growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global Peyronie’s disease treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc. 
• GlaxoSmithKline plc 
• Sanofi 
• Novartis AG 
• Merck & Co., Inc. 
• Johnson & Johnson 
• Bayer AG 
• AstraZeneca 
• AbbVie Inc. 
• Teva Pharmaceutical Industries Ltd. 
• Cipla Inc. 
• Sun Pharmaceutical Industries Ltd. 
• Mylan N.V. 
• Eli Lilly and Company 
• Takeda Pharmaceutical Company Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In November 2023, Endo International launched the PD Pool Hall video series to educate about Peyronie's disease, a men's health condition affecting 1 in 10 US men and potentially causing penis curvature deformity.

• In October 2021, Endo International launched the XIAFLEX television commercial, Bent Carrot, that introduces men to XIAFLEX, the first FDA-approved nonsurgical treatment for Peyronie's disease, encouraging them to seek treatment.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global Peyronie’s disease treatment market based on the below-mentioned segments: 

Global Peyronie’s Disease Treatment Market, By Route of Administration

• Oral
• Topical
• Injectable

Global Peyronie’s Disease Treatment Market, By Treatment

• Collagenase Injections
• Shockwave Therapy
• Surgery
• Oral Medications
• Topical Treatments

Global Peyronie’s Disease Treatment Market, By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Global Peyronie’s Disease Treatment Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa